Presentation Detail
Speaker
Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
Synopsis
Lymphoma is a common form of cancer found in dogs, but it is also known that its treatment can vary significantly. To handle the uniqueness of each cancer patient, ImpriMed provides a new method of analytic assistance to veterinary oncologists: analyzing immunophenotyping and chemosensitivity information using machine learning technology to predict the likelihood of success in various treatments. ImpriMed utilizes the advancement of functional precision medicine research for practical use in the veterinary field. We build upon traditional immunophenotyping with a proprietary chemosensitivity assay to test different drugs on each patients’ live cancer cells. Doctors receive comprehensive results from immunophenotyping assays: both Flow Cytometry and PARR (PCR for Antigen Receptor Rearrangement), in addition to our drug sensitivity test. By using big data analytics and machine learning-based predictive algorithms, we take the guesswork out of oncology by directly observing how a patient’s tumor is affected by drugs. ImpriMed helps oncologists personalize chemotherapy regimens by enabling a more informed decision for each patient’s cancer treatment.
